Primary endpoint | |
• Change in JPAC-QOL from baseline at 2 weeks | |
Key secondary endpoints | |
• Change in SBMs from baseline at 2 and 12 weeks | |
Other secondary endpoints | |
• Change in JPAC-QOL from baseline at 12 weeks | |
• Change in PAC-SYM from baseline at 2 and 12 weeks | |
• Change in CSS from baseline at 2 and 12 weeks | |
• Change in Rome IV from baseline at 2 and 12 weeks | |
• Change in BSFS from baseline at 2 and 12 weeks | |
• Change in SF-36 from baseline at 2 and 12 weeks | |
Safety endpoint | |
• Assessment of adverse events that appeared from days 1 to 28 after treatment |